Back to results
US 2023/0414627 A1Published application
Corticotropin releasing factor receptor antagonists
AssigneeSpruce Biosciences, Inc.
InventorsAlexis HOWERTON, Hal GERBER, Michael HUANG
Life of this patent
Estimating the term…
Abstract
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Claims21
A method for treating congenital adrenal hyperplasia (CAH) in a human, comprising:
- administering to said human a therapeutically-effective amount of a CRF1 receptor antagonist or a pharmaceutically acceptable salt thereof,
- wherein said human has received or has been previously determined to receive a first dose of a glucocorticoid, and
- administering to said human a second dose of a glucocorticoid, wherein said second dose of a glucocorticoid is reduced compared to said first dose of a glucocorticoid,
- wherein an androstenedione (A4) level in said subject is reduced from baseline, or
- wherein an adrenocorticotropic hormone (ACTH) level in said subject is reduced from baseline, or
- wherein a 17-hydroxyprogesterone (17-OHP) level in said subject is reduced from baseline.
3 more elements
Dependencies are inferred from the claim text.